astrazeneca.comAstraZeneca - Research-Based BioPharmaceutical Company

') Skip to content Skip to navigation Skip to footer Search Menu Search Search Search Close What science can do R&D R&D Our approach Transformative science Data science & AI Digital health Our technologies Next generation therapeutics Publications R&D strategic centres Our therapy areas All therapy areas Oncology BioPharmaceuticals Cardiovascular, Renal and Metabolism Respiratory & Immunology Other disease areas Pipeline All medicines Our company Our company Our strategy Our people Our commitment to patients Our leadership Cambridge Gothenburg Gaithersburg Careers Investors Investor Relations (Global) Investor Relations (Sweden) Resources Governance Shareholder information Dividend policy Key facts FAQs Debt Investors ADR Programme Media Press Releases Media centre Statements Articles Image library COVID-19 resources Broadcast videos Archive Media contacts Sustainability Sustainability Access to healthcare Environmental protection Ethics and transparency Supporting our communities Resources Partnering Partnering with AstraZeneca Our Partnering teams Our areas of partnering interest Why partner with AstraZeneca? Secrets to successful partnering Supplier Information More Hide AstraZeneca Websites Global site Our vaccine commitment Read more COVID-19 Information Hub Article Countering the counter-productive: it’s time for an alternative to SABA only asthma treatment Congratulations to Dr Susan Galbraith on being appointed Executive Vice President, Oncology R&D. An outstanding oncologist, Susan has a strong track record of delivering breakthrough science over the past decade at AstraZeneca, resulting in practice-changing new medicines to treat many types of cancer. Learn more about Dr Susan Galbraith Publications Our innovative science means a strong track-record of publication in peer-reviewed journals, contributing to the foundation of scientific advancement. View our publications We have 160 projects in our pipeline View pipeline Explore our technology Our Cambridge site (UK) is one of AstraZeneca's three global science centres Explore all our science centres Supporting our communities Wherever we work in the world, we aim to make a positive impact on people and the communities in which they live Corporate Press Release Lynparza in combination with abiraterone significantly delayed disease progression in all-comers in PROpel Phase III trial in 1st-line metastatic castration-resistant prostate cancer 24 September 2021 Corporate Press Release AstraZeneca to discover and develop self-amplifying RNA therapeutics in new collaboration with VaxEquity 23 September 2021 This website has geographical restrictions and may not display for certain regions. Would you like to visit site? Cancel Continue ? AstraZeneca Websites This website is intended for people seeking information on AstraZeneca's worldwide business. Our country sites can be located in the AZ Network. Veeva ID: Z4-25396 Date of next review: August 2022 Resources All resources Open Innovation Externally sponsored scientific research Medical Information for HCPs US prescription assistance programmes Global clinical trials information Medicines Report a possible side effect Quick links Media Investor Relations Partnering Careers Sustainability Modern Slavery Statement AZethics – Report A Concern Supplier information Social Media Community Guidelines Social Media LinkedIn Twitter YouTube Instagram Glassdoor Facebook utility links Legal notice and Terms of Use Privacy notice Site map Contact us Cookie policy © AstraZeneca 2021 You are now leaving AstraZeneca.com You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. Cancel Continue ? Important notice for users You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information. I have read this warning and will not be using any of the contained product information for clinical purposes. I disagree I agree ? ?...